Observations on hydrocodone and its metabolites in oral fluid specimens of the pain population: Comparison with urine

Jennifer M. Cao, BS; Joseph D. Ma, PharmD; Candis M. Morello, PharmD, CDE; Rabia S. Atayee, PharmD, BCPS; Brookie M. Best, PharmD, MAS

doi:10.5055/jom.2014.0206

Authors

Jennifer M. Cao, BS
Joseph D. Ma, PharmD
Candis M. Morello, PharmD, CDE
Rabia S. Atayee, PharmD, BCPS
Brookie M. Best, PharmD, MAS

DOI:

https://doi.org/10.5055/jom.2014.0206

Keywords:

hydrocodone, norhydrocodone, hydromorphone, metabolism, excretion, oral fluid

Abstract

Objective: Hydrocodone undergoes metabolism via cytochrome P450 (CYP) 3A4 (N-demethylation) to norhydrocodone and via CYP2D6 (O-demethylation) to hydromorphone. Hydrocodone, hydromorphone, and norhydrocodone are excreted in urine and secreted in saliva. The goal was to characterize hydrocodone and its metabolites in oral fluid specimens of a pain population and compare to urine specimens.

Design: This retrospective analysis included more than 8,500 oral fluid specimens and more than 250,000 urine specimens collected between March and June 2012 that were sent to Millennium Laboratories (San Diego, CA) and analyzed for hydrocodone, hydromorphone, and norhydrocodone using liquid chromatography-tandem mass spectrometry. Statistical analyses and linear regressions were conducted using Microsoft Excel® 2010 and OriginPro v8.6.

Results: The median oral fluid concentrations of hydrocodone and norhydrocodone were 122 and 7.7 ng/mL, respectively. However, the oral fluid concentrations of hydromorphone were below detection in many specimens (<1 ng/mL). The positive detection rate of parent drug and metabolites in oral fluid (17-31 percent detection rates) was much lower than in urine (63-75 percent detection rates). The geometric median metabolic ratio (MR) of norhydrocodone to hydrocodone was 0.07 in oral fluid and 1.2 in urine. The observed hydrocodone oral fluid concentrations were approximately 10-fold greater than previously reported plasma concentrations.

Conclusion: Oral fluid had a much lower norhydrocodone to hydrocodone MR compared to urine. Reference ranges for oral fluid drug concentrations should not be extrapolated from plasma ranges. The observed ranges of secreted hydrocodone and metabolite concentrations in oral fluid should help determine reference ranges for medication monitoring.

Author Biographies

Jennifer M. Cao, BS

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego (UC San Diego), La Jolla, California

Joseph D. Ma, PharmD

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego (UC San Diego), La Jolla, California; Doris A. Howell Palliative Care Service, San Diego, California.

Candis M. Morello, PharmD, CDE

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego (UC San Diego), La Jolla, California; Diabetes Intense Medical Management Clinic, Veterans Affairs San Diego Healthcare System, La Jolla, California.

Rabia S. Atayee, PharmD, BCPS

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego (UC San Diego), La Jolla, California; Doris A. Howell Palliative Care Service, San Diego, California.

Brookie M. Best, PharmD, MAS

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego (UC San Diego), La Jolla, California; UC San Diego Department of Pediatrics, Rady Children’s Hospital, San Diego, California.

References

IMS: Top 25 U.S. Pharmaceutical Products by Dispensed Prescriptions. Danbury, CT: IMS, 2012.

Chou R, Fanciullo GJ, Fine PG, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.

Hutchinson MR, Menelaou A, Foster DJ, et al.: CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol. 2003; 57(3): 287-297.

Oyler JM, Cone EJ, Joseph RE Jr, et al.: Identification of hydrocodone in human urine following controlled codeine administration. J Anal Toxicol. 2000; 24(7): 530-535.

Cone EJ, Presley L, Lehrer M, et al.: Oral fluid testing for drugs of abuse: Positive prevalence rates by Intercept immunoassay screening and GC-MS-MS confirmation and suggested cutoff concentrations. J Anal Toxicol. 2002; 26(8): 541-546.

Heltsley R, DePriest A, Black DL, et al.: Oral fluid drug testing of chronic pain patients. I. Positive prevalence rates of licit and illicit drugs. J Anal Toxicol. 2011; 35(8): 529-540.

Speckl IM, Hallbach J, Guder WG, et al.: Opiate detection in saliva and urine—A prospective comparison by gas chromatography-mass spectrometry. J Toxicol Clin Toxicol. 1999; 37(4): 441-445.

Yacoubian GS Jr, Wish ED, Perez DM: A comparison of saliva testing to urinalysis in an arrestee population. J Psychoactive Drugs. 2001; 33(3): 289-294.

Cone EJ, Huestis MA: Interpretation of oral fluid tests for drugs of abuse. Ann N Y Acad Sci. 2007; 1098: 51-103.

Niedbala RS, Kardos KW, Fritch DF, et al.: Detection of marijuana use by oral fluid and urine analysis following single-dose administration of smoked and oral marijuana. J Anal Toxicol. 2001; 25(5): 289-303.

Heltsley R, Depriest A, Black DL, et al.: Oral fluid drug testing of chronic pain patients. II. Comparison of paired oral fluid and urine specimens. J Anal Toxicol. 2012; 36(2): 75-80.

Haeckel R: Factors influencing the saliva/plasma ratio of drugs. Ann N Y Acad Sci. 1993; 694: 128-142.

Pesce A, West C, West R, et al.: Determination of medication cutoff values in a pain patient population. J Opioid Manag. 2011; 7(2): 117-122.

Tuyay J, Coulter C, Rodrigues W, et al.: Disposition of opioids in oral fluid: Importance of chromatography and mass spectral transitions in LC-MS/MS. Drug Test Anal. 2012; 4(6): 395-401.

Cone EJ, Darwin WD, Gorodetzky CW, et al.: Comparative metabolism of hydrocodone in man, rat, guinea pig, rabbit, and dog. Drug Metab Dispos. 1978; 6(4): 488-493.

Tetko IV, Gasteiger J, Todeschini R, et al.: Virtual computational chemistry laboratory—Design and description, J Comput Aid Mol Des. 2005; 19: 453-463

Advanced Chemistry Development Sofware V11.02 [computer program].Toronto, Ontario, Canada: Advanced Chemistry Development, Inc.1994-2012.

Kim I, Barnes AJ, Oyler JM, et al.: Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration. Clin Chem. 2002; 48(9): 1486-1496.

Molina DK, Hargrove VM: What is the lethal concentration of hydrocodone? A comparison of postmortem hydrocodone concentrations in lethal and incidental intoxications. Am J Forensic Med Pathol. 2011; 32(2): 108-111.

Baker DD, Jenkins AJ: A comparison of methadone, oxycodone, and hydrocodone related deaths in Northeast Ohio. J Anal Toxicol. 2008; 32(2): 165-171.

Spiller HA: Postmortem oxycodone and hydrocodone blood concentrations. J Forensic Sci. 2003; 48(2): 429-431.

Barnhart JW, Caldwell WJ: Gas chromatographic determination of hydrocodone in serum. J Chromatogr. 1977; 130: 243-249.

Jannetto PJ, Bratanow NC: Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomics. 2009; 10(7): 1157-1167.

Haeckel R, Hanecke P: Application of saliva for drug monitoring. An in vivo model for transmembrane transport. Eur J Clin Chem Clin Biochem. 1996; 34(3): 171-191.

Baselt RC: Disposition of Toxic Drugs and Chemicals in Man, 9th ed. Seal Beach, CA: Biomedical Publications, 2011.

Dickinson RG, Hooper WD, King AR, et al.: Fallacious results from measuring salivary carbamazepine concentrations. Ther Drug Monit. 1985; 7(1): 41-45.

O’Neal CL, Crouch DJ, Rollins DE, et al.: Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration. J Anal Toxicol. 1999; 23(6): 452-459.

Vondracek M, Xi Z, Larsson P, et al.: Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis. 2001; 22(3): 481-488.